Dr. Ralph V. Boccia, M.D.

Medicare patients and services

Medicare patients, 2024

894

Services billed

329,605

Patients’ average age

78

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 61 companies reported 326 payments worth $244,074 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Maryland →

Industry-funded research

Named as a principal investigator on 35 industry-funded studies in 2025, from 13 companies. The companies reported $1,445,796 in research payments for these studies, mostly to the institutions running them.

• Longitudinal Multi-Center Chart Review Data Repository For Multiple Myeloma
  Janssen Scientific Affairs, LLC
• Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy
  Genentech, Inc.
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
  AbbVie Inc. · Recruiting · NCT06428019
• An open-label, multicenter phase 1B study investigating the safety of TAK-079 in combination with backbone regimens for the treatment of patients with newly diagnosed multiple myeloma and for whom stem cell transplant…
  Takeda Pharmaceuticals U.S.A., Inc.
• A phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell…
  AstraZeneca UK Limited
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
  Daiichi Sankyo Inc. · Active, not recruiting · NCT04042701
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
  Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732
• M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
  AbbVie Inc.
• M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
  AbbVie Inc.
• A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
  Celgene Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Bethesda

• Philip M. Arlen, M.D.
• Kevin Babcock
• Sanjeeve Balasubramaniam, MD
• Peter A. Beale, M.D.
• Wendy B. Bernstein, MD
• Gideon M. Blumenthal, M.D.
• Daniel Bowers, M.D.
• Corey A. Carter, M.D.